{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T15:10:15Z","timestamp":1759590615472,"version":"build-2065373602"},"reference-count":18,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,8,17]],"date-time":"2020-08-17T00:00:00Z","timestamp":1597622400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Roche Pharma AG, Grenzach-Wyhlen, Germany"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Neurology and Neurosurgery"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.clineuro.2020.106142","type":"journal-article","created":{"date-parts":[[2020,8,12]],"date-time":"2020-08-12T11:55:30Z","timestamp":1597233330000},"page":"106142","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Ocrelizumab Treatment in Patients with Primary Progressive Multiple Sclerosis: Short-term Safety Results from a Compassionate Use Programme in Germany"],"prefix":"10.1016","volume":"197","author":[{"given":"Sebastian","family":"Rauer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muna-Miriam","family":"Hoshi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Refik","family":"Pul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mathias","family":"Wahl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Schwab","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judith","family":"Haas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gisa","family":"Ellrichmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Krumbholz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bj\u00f6rn","family":"Tackenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kai-Uwe","family":"Saum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabian","family":"Buck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jost","family":"Leemhuis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anita","family":"Kretschmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Orhan","family":"Aktas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.clineuro.2020.106142_bib0005","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1080\/14712598.2019.1611778","article-title":"CD20 monoclonal antibodies for the treatment of multiple sclerosis: up-to-date","volume":"19","author":"Ancau","year":"2019","journal-title":"Expert Opin Biol Ther"},{"issue":"5","key":"10.1016\/j.clineuro.2020.106142_bib0010","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s00401-012-0953-0","article-title":"Primary progressive multiple sclerosis: part of the MS disease spectrum or separate disease entity?","volume":"123","author":"Antel","year":"2012","journal-title":"Acta Neuropathol"},{"issue":"4","key":"10.1016\/j.clineuro.2020.106142_bib0015","doi-asserted-by":"crossref","first-page":"244","DOI":"10.5582\/irdr.2016.01054","article-title":"An overview of Compassionate Use Programs in the European Union member states","volume":"5","author":"Balasubramanian","year":"2016","journal-title":"Intractable Rare Dis Res"},{"issue":"20","key":"10.1016\/j.clineuro.2020.106142_bib0020","doi-asserted-by":"crossref","first-page":"4834","DOI":"10.1182\/blood-2008-10-186999","article-title":"Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project","volume":"113","author":"Carson","year":"2009","journal-title":"Blood"},{"year":"2018","author":"EMA","series-title":"Ocrevus: EPAR - Product Information","key":"10.1016\/j.clineuro.2020.106142_bib0025"},{"issue":"5","key":"10.1016\/j.clineuro.2020.106142_bib0030","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1111\/ene.13581","article-title":"Survey of diagnostic and treatment practices for multiple sclerosis (MS) in Europe. Part 2: Progressive MS, paediatric MS, pregnancy and general management","volume":"25","author":"Fernandez","year":"2018","journal-title":"Eur. J. Neurol."},{"issue":"3","key":"10.1016\/j.clineuro.2020.106142_bib0035","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa1601277","article-title":"Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis","volume":"376","author":"Hauser","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.clineuro.2020.106142_bib0040","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1002\/ana.21880","article-title":"Bleak prospects for primary progressive multiple sclerosis therapy: downs and downs, but a glimmer of hope","volume":"66","author":"Hartung","year":"2009","journal-title":"Ann. Neurol."},{"issue":"4","key":"10.1016\/j.clineuro.2020.106142_bib0045","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1002\/ana.21867","article-title":"Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial","volume":"66","author":"Hawker","year":"2009","journal-title":"Ann. Neurol."},{"issue":"12","key":"10.1016\/j.clineuro.2020.106142_bib0050","first-page":"423","article-title":"Ocrelizumab: its efficacy and safety in multiple sclerosis","volume":"66","author":"Juanatey","year":"2018","journal-title":"Rev. Neurol."},{"key":"10.1016\/j.clineuro.2020.106142_bib0055","article-title":"Anti-inflammatory disease-modifying treatment and disability progression in primary progressive multiple sclerosis: a cohort study","author":"Lorscheider","year":"2018","journal-title":"Eur J Neurol."},{"issue":"10","key":"10.1016\/j.clineuro.2020.106142_bib0060","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/S1474-4422(07)70243-0","article-title":"Primary-progressive multiple sclerosis","volume":"6","author":"Miller","year":"2007","journal-title":"Lancet Neurol"},{"issue":"1","key":"10.1016\/j.clineuro.2020.106142_bib0065","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1186\/s13104-017-2687-5","article-title":"Characterizing expanded access and compassionate use programs for experimental drugs","volume":"10","author":"Miller","year":"2017","journal-title":"BMC Res Notes"},{"issue":"3","key":"10.1016\/j.clineuro.2020.106142_bib0070","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1606468","article-title":"Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis","volume":"376","author":"Montalban","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.clineuro.2020.106142_bib0075","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/ana.22366","article-title":"Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria","volume":"69","author":"Polman","year":"2011","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.clineuro.2020.106142_bib0080","article-title":"https:\/\/www. ocrelizumabinfo. global\/en\/homepage. html Accessed May 26, 2020. F","author":"Roche","year":"2020","journal-title":"Hoffmann La -Roche Ltd."},{"issue":"7","key":"10.1016\/j.clineuro.2020.106142_bib0085","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1177\/1352458517711274","article-title":"A contemporary profile of primary progressive multiple sclerosis participants from the NARCOMS Registry","volume":"24","author":"Salter","year":"2018","journal-title":"Mult. Scler."},{"year":"2017","author":"US-FDA","series-title":"Ocrevus prescribing information","key":"10.1016\/j.clineuro.2020.106142_bib0090"}],"container-title":["Clinical Neurology and Neurosurgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0303846720304856?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0303846720304856?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T14:37:12Z","timestamp":1759588632000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0303846720304856"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":18,"alternative-id":["S0303846720304856"],"URL":"https:\/\/doi.org\/10.1016\/j.clineuro.2020.106142","relation":{},"ISSN":["0303-8467"],"issn-type":[{"type":"print","value":"0303-8467"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ocrelizumab Treatment in Patients with Primary Progressive Multiple Sclerosis: Short-term Safety Results from a Compassionate Use Programme in Germany","name":"articletitle","label":"Article Title"},{"value":"Clinical Neurology and Neurosurgery","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clineuro.2020.106142","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106142"}}